European Congresses

This year marked the 22nd EHA Congress, which was held for the first time in Madrid from 22 to 25 June. The Annual Congress provides a forum for presenting original unpublished data and disseminating evidence-based knowledge of primary clinical relevance.

Dr. John G. Gribben, EHA new President elect and a member of LC Medical Advisory Board, presented an excellent overview of the latest lymphoma and CLL updates at EHA during the advocacy capacity-building session (see his slides).

Anita Waldman, LHRM Chair and a founding member of the LC, remarkably illustrated the patient perspective in the Quality of life session, reminding that most onco-hematological patients experience long-term side-effects – such as fatigue, memory loss, fear of relapse –and need support in the long run.

Many scientific sessions were dedicated to lymphomas, including indolent, aggressive and rare lymphoma subtypes. While the treatment options continue to develop in many areas, Prof. Gilles Salles highlighted in his educational talk on relapsed-refractory DLBCL the unmet needs that some categories of lymphoma patients still experience.

For further updates on EHA scientific sessions, consult LC partners  


IMG 20170614 WA0004c

EHA Patient Advocacy Booth


20170622 155516a 

Prof. John Gribben - EHA Capacity Building Session


20170623 101925a

Anita Waldman - Hematological malignancies: The patient's voice


20170625 102540

Gilles Salles - Relapsed agressive lymphoma


20170625 100243a

Gilles Salles - Relapsed agressive lymphoma


20170624 104653

Dr. Stephan Ansell - Immunological approaches in MCL


Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 05/30/17. Copyright © 2017 Lymphoma Coalition. All rights reserved.